Home›Trial›NCT05929079
🔬NCT05929079Phase 3ACTIVE NOT RECRUITING

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Study Summary

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Conditions
Type 2 DiabetesObesityOverweightObstructive Sleep Apnea
Interventions / Drugs
RetatrutidePlacebo
View on ClinicalTrials.gov ↗
Sponsor
LLY
Eli Lilly and Company
Diabetes/Oncology
C53/100
Study Details
Enrollment1000 participants
Primary Completion—
Lead SponsorEli Lilly and Company
Data Retrieved2026-04-11 02:55:33.865935+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.